Aptevo Therapeutics (APVO) to Release Quarterly Earnings on Friday

Aptevo Therapeutics (NASDAQ:APVO) will likely be announcing its results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($8.09) per share for the quarter.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($40.14) EPS for the quarter, missing analysts’ consensus estimates of ($37.62) by ($2.52). On average, analysts expect Aptevo Therapeutics to post $-16 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Aptevo Therapeutics Price Performance

APVO stock opened at $6.01 on Friday. The company has a 50 day moving average price of $13.64 and a 200 day moving average price of $25.56. Aptevo Therapeutics has a fifty-two week low of $5.94 and a fifty-two week high of $1,551.60. The stock has a market capitalization of $6.00 million, a PE ratio of 0.00 and a beta of 1.49.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned about 1.16% of Aptevo Therapeutics as of its most recent SEC filing. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

APVO has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Aptevo Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.